| Customization: | Available |
|---|---|
| Transport Package: | Carton |
| Specification: | 100mcg/1ml |
|
Still deciding? Get samples of US$ 0.1/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Generic Name | Octreotide Acetate Injection 100mcg/1ml |
| Strength | 100mcg/1ml |
| Packing | 10Ampoules/box |
| Origin | China |
1. Emergency treatment of esophageal and gastric variceal bleeding due to cirrhosis, in combination with special treatment, such as endoscopic sclerotherapy.
2. Relieve symptoms and signs associated with gastrointestinal and pancreatic endocrine tumors. There is sufficient evidence that octreotide is effective against: carcinoid tumors with carcinoid syndrome; The response rate of octreotide against the following tumors is about 50%.
(1) gastrinoma /Zollinger-Ellison syndrome (usually used in combination with selective H2 receptor antagonists, with antacids as appropriate).
(2) islet tumor (used to prevent hypoglycemia and maintain normal blood sugar before islet tumor).
(3) Growth hormone releasing factor tumor. Octreotide acetate therapy only relieves symptoms and signs, not cures them.
3. Prevent postoperative complications of pancreas
4. In patients with acromegaly who have failed therapy with surgery, radiotherapy or dopamine receptor agonists, symptoms can be controlled and concentrations of growth hormone and auxin mediators C reduced. This product is also indicated for patients with acromegaly who are unable or unwilling to undergo surgery, and for patients with intermittent periods who have not responded to radiation therapy.
1. Esophageal - fundus varicose vein bleeding
First, 0.1mg was injected intravenously (5 min), then 0.6mg was dissolved in 500ml 5% glucose, and was continuously injected intravenously through an infusion pump at the rate of 50μg/ h, once in 12 hours. The maximum treatment is 5 days.
2. Gastrointestinal and pancreatic endocrine tumors
The initial dose was 0.05mg subcutaneously injected once or twice a day. The dose can be gradually increased to 0.2mg three times daily, depending on tolerance and efficacy (clinical response, hormone concentration secreted by the tumor). Higher doses may be administered only in certain circumstances. Maintenance should be based on individual differences. Octreotide acetate should not be administered for more than one week if clinical symptoms and laboratory results show no improvement.
3. Prevent complications after pancreatic surgery
Subcutaneous injection of 0.1mg was given three times a day for maintenance treatment for 7 days, and the first injection should be given at least 1 hour before surgery.
4. Acromegaly
The initial dose was 0.05-0.1 mg subcutaneously administered every 8 hours, adjusted according to monthly assessment of circulating growth hormone concentration, clinical response, and tolerance (target: GH < 2.5ng/ml, normal IGF range >). The optimal dose for most patients is 0.2 ~ 0.3mg/ day. The maximum dose should not exceed 1.5mg/ day. Reduction may be appropriate after several months of treatment under the guidance of monitoring plasma growth hormone levels.
After one month of octreotide acetate treatment, discontinuation should be considered if there is no decrease in growth hormone concentration and no improvement in clinical symptoms.
Taboo:
It is forbidden for allergic person.
Precautions:
Because somato-secreting pituitary tumors can sometimes spread and cause serious complications (such as visual field defects), all patients should be carefully observed and other treatments should be considered if signs of tumor spread are found.
Gallstone formation has been reported in 10 ~ 20% of patients with long-term use of octreotide acetate. Therefore, ultrasonic examination of gallbladder should be performed every 6 ~ 12 months before treatment and after medication.
In patients with islet tumor, octreotide acetate may increase the degree and duration of hypoglycemia because it inhibits GH and glucagon secretion more than insulin secretion. Such patients should be closely observed especially at the beginning of octreotide acetate therapy or dose changes. Frequent administration of octreotide acetate in small doses can reduce significant fluctuations in blood glucose concentration. Octreotide may alter insulin requirements in patients with type I diabetes mellitus (insulin-dependent). Postprandial blood sugar increase in non-diabetic patients and type II diabetes patients with partial insulin function.
Esophageal and fundus variceal bleeding may increase the risk of insulin dependent diabetes mellitus and lead to changes in insulin requirements. Therefore, blood sugar levels should be closely monitored.
){kind=link}